Skip to main content
Premium Trial:

Request an Annual Quote

Amgen, Illumina, Wyeth, Affymetrix, HistoRx, BobCat, GenoSensor

Amgen to Use Illumina Genotyping Technology in Large Women's Health Study
Illumina last week said that Amgen will use its genotyping technology as part of a large women's health study. 
Under the agreement, Illumina will provide its HumanHap300-Duo BeadChip to Amgen, which will work with researchers at the Brigham and Women’s Hospital to genotype women who have been clinically tracked for a decade.
The research is part of the Women’s Genome Health Study, which follows 28,000 women in an effort to identify genetic variations to try to find genetic clues to illnesses such as heart disease, diabetes, breast cancer, osteoporosis, and others
Financial terms of the deal were not disclosed.

Wyeth Extends Affymetrix Supply Deal for Three More Years
Wyeth has extended an ongoing microarray supply agreement with Affymetrix for three more years, Affymetrix said last week.
Under the terms of the agreement, originally signed in 1994, Wyeth will continue to use Affy’s GeneChip technology to identify new drug targets and to study genetic markers linked to therapeutic response.
Affy said Wyeth also uses its GeneChip products for disease classification and in predicting clinical progression.
No financial terms of the deal were released.

HistoRx Licenses AQUA Rights to Four Centers
HistoRx last week said it has licensed its AQUA biomarker-analysis technology to four research institutes.
The non-commercial agreements went to Brigham and Women’s Hospital, the Mayo Clinic, the Lee Moffitt Cancer Center and Research Institute, and the University of Wisconsin-Madison’s School of Medicine and Public Health.
HistoRx said these institutes will use the platform to measure localization and concentration of clinically relevant proteins in diseased tissues, which will aid in developing drugs and in making treatment decisions.

BobCat to Distribute GenoSensor’s GenoExplorer Chips in Europe
GenoSensor this week said that it has signed a distribution deal with the German life sciences company BioCat.
Under the terms of the agreement, BioCat will exclusively distribute Tempe, Ariz.-based GenoSensor’s GenoExplorer miRNA array products throughout the European Union.
Further details were not discussed.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.